Previous 10 | Next 10 |
Sonnet BioTherapeutics Holdings (NASDAQ: SONN ) +100% . More news on: Sonnet BioTherapeutics Holdings, Inc., MEI Pharma, Inc., NantKwest, Inc., Stocks on the move, Read more ...
Will These Penny Stocks Be On Your Buy List This Week? When you think about penny stocks , you probably rarely think that they’d amount to much more than a quick flip. But this year, as many have already learned, people are investing in penny stocks for real potential. Some may call it...
MEI Pharma (NASDAQ: MEIP ) jumps 77% premarket on robust volume in reaction to its agreement with Kyowa Kirin Co., Ltd. ( OTCPK:KYKOF ) to co-develop and co-promote Phase 2-stage ME-401 in the U.S. for the treatment of B-cell blood cancers. More news on: MEI Pharma, Inc., Kyo...
SAN DIEGO and TOKYO , April 14, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today jointly announced that the companies have entered into a global license, development and commercialization agreement to further develop and ...
SAN DIEGO , April 8, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that Daniel P. Gold , Ph.D., president and chief executive officer, will present an overview and business update a...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
The FDA has granted Fast Track designation to MEI Pharma's (NASDAQ: MEIP ) ME-401, an investigational selective oral inhibitor of phosphatidylinositol 3-kinase ("PI3K") delta for the treatment of adult Patients with relapsed or refractory follicular lymphoma who have received at least two ...
SAN DIEGO , March 31, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA ) granted Fast Track designation to ME-401, MEI's investig...
MEI Pharma (NASDAQ: MEIP ): Q2 GAAP EPS of -$0.26 misses by $0.09 . More news on: MEI Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO , Feb. 6, 2020 /PRNewswire/ -- MEI Pharma, Inc. (NASDAQ: MEIP) ("MEI"), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today reported results for its second quarter ended December 31, 2019 . "We're off to a good start in calendar year 2020....
News, Short Squeeze, Breakout and More Instantly...
-- Ongoing Phase 1 Study Evaluating Voruciclib Plus Venetoclax Demonstrates Anti-leukemic Activity, Including Complete Responses, Anticipated Decreases in Mcl-1 and No Overlapping Toxicity in Heavily Pretreated R/R AML Patients -- -- Board of Directors Unanimously Aligned on Prioritizatio...
– MEI Pharma Board Unanimously Determines, Based on Clinical Data Results, Not to Proceed with Second Capital Return Under 2023 Anson and Cable Car Cooperation Agreement: Conserving Capital, Prioritizing Measured Investment, Extending Operational Runway – MEI Pharma, Inc. ...